[Not Available].
作者信息
Fischer Benedikt, Moghimi Elnaz, Weekes John
机构信息
Faculté des sciences de la santé (Fischer), Simon Fraser University, Vancouver, C.-B.; Research & Graduate Studies (Fischer), University of the Fraser Valley, Abbotsford, C.-B.; Waypoint Research Institute, Waypoint Centre for Mental Health (Fischer, Moghimi), Penetanguishene, Ont.; Département de psychiatrie (Fischer), University of Toronto, Toronto, Ont.; Département de psychiatrie (Moghimi), Queen's University, Kingston, Ont.; Centre canadien sur les dépendances et l'usage de substances (Weekes); Département de psychologie (Weekes), Carleton University, Ottawa, Ont.
出版信息
CMAJ. 2025 Mar 16;197(10):E283-E285. doi: 10.1503/cmaj.241661-f.
Abstract
摘要
相似文献
1
[Not Available].[无可用内容]
CMAJ. 2025 Mar 16;197(10):E283-E285. doi: 10.1503/cmaj.241661-f.
本文引用的文献
1
Cost-benefit analysis of Canada's Prison Needle Exchange Program for the prevention of hepatitis C and injection-related infections.加拿大监狱针头交换项目预防丙型肝炎及注射相关感染的成本效益分析。
CMAJ. 2024 Dec 15;196(43):E1401-E1412. doi: 10.1503/cmaj.240648.
2
Interventions to reduce harms related to drug use among people who experience incarceration: systematic review and meta-analysis.干预措施以减少监禁人群中与药物使用相关的危害：系统评价和荟萃分析。
Lancet Public Health. 2024 Sep;9(9):e684-e699. doi: 10.1016/S2468-2667(24)00160-9.
3
Rates and causes of death after release from incarceration among 1 471 526 people in eight high-income and middle-income countries: an individual participant data meta-analysis.在八个高收入和中等收入国家中，从监禁中释放后 1471526 人的死亡率和死亡原因：一项个体参与者数据荟萃分析。
Lancet. 2024 May 4;403(10438):1779-1788. doi: 10.1016/S0140-6736(24)00344-1. Epub 2024 Apr 10.
4
Prescribed safer opioid supply: A scoping review of the evidence.规定更安全的阿片类药物供应：证据的范围综述。
Int J Drug Policy. 2024 Mar;125:104339. doi: 10.1016/j.drugpo.2024.104339. Epub 2024 Feb 9.
5
Effect of Risk Mitigation Guidance opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: retrospective cohort study.风险缓解指导下阿片类药物和兴奋剂配给对双重公共卫生紧急情况下的死亡率和急性护理就诊的影响：回顾性队列研究。
BMJ. 2024 Jan 10;384:e076336. doi: 10.1136/bmj-2023-076336.
6
Burden of opioid toxicity death in the fentanyl-dominant era for people who experience incarceration in Ontario, Canada, 2015-2020: a whole population retrospective cohort study.2015-2020 年加拿大安大略省监禁人群中芬太尼主导时期阿片类药物毒性死亡负担：一项全人群回顾性队列研究。
BMJ Open. 2023 May 10;13(5):e071867. doi: 10.1136/bmjopen-2023-071867.
7
Anticipated Barriers to Sustained Engagement in Treatment With Medications for Opioid Use Disorder After Release From Incarceration.监禁释放后，持续使用药物治疗阿片类药物使用障碍过程中预期的参与障碍。
J Addict Med. 2023;17(1):54-59. doi: 10.1097/ADM.0000000000001029. Epub 2022 Aug 2.
8
Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada.加拿大安大略省从联邦监禁中释放到社区的个体参与阿片类激动剂治疗（OAT）的障碍和促进因素。
Int J Qual Stud Health Well-being. 2022 Dec;17(1):2094111. doi: 10.1080/17482631.2022.2094111.
9
The prevalence of comorbid serious mental illnesses and substance use disorders in prison populations: a systematic review and meta-analysis.监狱人群中合并严重精神疾病和物质使用障碍的患病率：系统评价和荟萃分析。
Lancet Public Health. 2022 Jun;7(6):e557-e568. doi: 10.1016/S2468-2667(22)00093-7.
10
Rates of opioid agonist treatment prescribing in provincial prisons in Ontario, Canada, 2015-2018: a repeated cross-sectional analysis.2015-2018 年加拿大安大略省省级监狱中阿片类激动剂治疗处方率：一项重复横断面分析。
BMJ Open. 2021 Nov 18;11(11):e048944. doi: 10.1136/bmjopen-2021-048944.
Zotero 插件